Gene Silencing Market
Gene Silencing Market Scope: Industry Analysis, Market Size, Growth, Trends Till 2031
Request Sample Report
Gene Silencing Market Size and Growth
The Gene Silencing market is experiencing significant growth, driven by advancements in RNA interference and CRISPR technologies. Valued at approximately $5.2 billion in 2023, it is projected to reach $12 billion by 2030. Increasing demand for targeted therapies and personalized medicine is influencing market trends and investment strategies.
Companies Covered
(Covid 19 Impact Covered)
◍ Alnylam Pharmaceuticals
◍ Benitec Biopharma
◍ Arrowhead Pharmaceuticals
◍ Merck Group
◍ Eli Lilly (Dicerna Pharmaceuticals)
◍ Monsanto (Bayer AG)
◍ RXi Pharmaceuticals
◍ Silence Therapeutics plc
◍ Idera Pharmaceuticals
The gene silencing market features companies like Alnylam Pharmaceuticals and Merck Group pioneering RNA interference therapies. They drive innovation, expanding applications in genomics and therapeutics. Benitec and Arrowhead focus on proprietary technologies, enhancing market growth. Sales figures highlight strong investment, with Alnylam reporting $1.3 billion in 2022 revenues.
Request Sample Report
Market Segmentation
By Application
Cancer Treatment
Neurological Diseases Treatment
Scar Treatment
Other Request Sample Report
By Product
Transcriptional
Post-transcriptional
Meiotic
Market Growth
Request Sample Report
$ 9.13 Billion
